NICE approves Sovaldi
January 16, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi
NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …
Boehringer complaint ruled out by PMCPA
January 15, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, COPD, PMCPA, Striverdi, olodaterol
A complaint made by a pharmacist stating that the artwork image for Boehringer Ingelheim’s COPD drug Striverdi is misleading has …
Sanofi and Boehringer partner on biologics manufacturing
January 15, 2015Manufacturing and Production, Sales and Marketing Boehringer, Sanofi, antibodies, biologics, cardiovascular, diabetes, mabs, manufacturing, monoclonal, oncology
Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …
Sharing trial data should be ‘expected norm’ says US think-tank
January 15, 2015Medical Communications, Research and Development, Sales and Marketing FDA, Goldacre, Institute of Medicine, clinical trials, transparency
Clinical trial data is in the public interest and should be shared no less than 30 days following regulatory approval …
NICE releases reflux disease guidelines
January 15, 2015Sales and Marketing NHS, NICE, UK, gor, gord, h2ra
NICE has released new guidelines providing doctors with advice on how to treat gastro-oesophageal reflux disease (GORD) in young people. …
HSCIC appoints new specialist
January 15, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HSCIC, andy kinnear
The Health and Social Care Information Centre (HSCIC) has appointed Andy Kinnear as a specialist. He will join the organisation …
AstraZeneca’s troubled Brilinta gets welcome lift
January 14, 2015Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor
AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …
Biogen Idec buys Convergence
January 14, 2015Sales and Marketing BG00010, Biogen IDEC, CNV1014802, Colombia University Medical Center, Convergence, Neublastin
Biogen Idec is to acquire independent UK-based Convergence Pharmaceuticals to strengthen its pipeline of drugs for pain management in a …
BMS Opdivo trial scores early goal
January 14, 2015Research and Development, Sales and Marketing BMS, Merck, cancer nsclc, keytruda, nivolumab, opdivo
A late-stage trial of Bristol-Myers Squibb’s lung cancer drug Opdivo has been stopped early after showing promising results – but …
Immunocore names chief executive
January 14, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eliot Forster, immunocore
Oxford-based biotec Immunocore has announced the appointment of Dr Eliot Forster as its chief executive with immediate effect. Forster takes …
Lilly, BMS and Merck unite for cancer trials
January 13, 2015Research and Development, Sales and Marketing BMS, Cancer, Galunisertib, Merck, NSCLC, keytruda, lilly, oncology, opdivo
Lilly will test some of its compounds in combination with rival cancer drugs from Bristol-Myers Squibb and Merck, the companies …
Roche teams up to tackle antibiotics resistance
January 13, 2015Research and Development, Sales and Marketing Antibiotics, Fedora, Meiji, OP0595, Roche, Teixobactin
Roche is to collaborate with Japan-based pharma firm Meiji and Canadian Fedora – two companies specialising in the production of …
New UCB chief starts and expands team
January 13, 2015Sales and Marketing Cimzia, Jean-Christophe Tellier, Neupro, UCB, roch deliveux, vimpat
New UCB chief executive Jean-Christophe Tellier who succeeded Roch Doliveux this year has also welcomed three new members to the …
AMRI buys two Aptuit facilities
January 13, 2015Manufacturing and Production AMRI, Aptuit, cedarburg, glasgow, oso
Contract research and manufacturing firm AMRI has acquired two businesses from pharmaceutical services company Aptuit in a $60 million deal. …
Oryzon Genomics names CFO and executive VP
January 13, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gregory Weaver, Oryzon genomics
Spanish clinical stage biopharma firm Oryzon Genomics has appointed Gregory Weaver as its executive vice president and chief financial officer. …
Another NICE no for Dendreon cancer drug
January 13, 2015Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T
Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
Novartis enters digital tech collaboration
January 12, 2015Sales and Marketing Novartis, clinical trials, digital, mhealth, qualcomm, ventures
Novartis has entered an agreement with the US investment company Qualcomm Ventures to create a joint firm to support the …
Shire buys rare-disease firm NPS Pharma
January 12, 2015Sales and Marketing AbbVie, Shire, gattex, natpara, nps, nps pharma
Shire is to acquire rare diseases firm NPS Pharma to enhance its profile following the collapse of its deal with …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
